|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 9/20 | |
| A61K 38/26 | |||
| A61K 31/195 | |||
| A61P 3/04 | |||
| A61P 3/10 |
| (11) | Number of the document | 3326620 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17204363.0 |
| Date of filing the European patent application | 2011-12-16 | |
| (97) | Date of publication of the European application | 2018-05-30 |
| (45) | Date of publication and mention of the grant of the patent | 2020-03-04 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 10195285 | 2010-12-16 | EP | |
| 201061425087 P | 2010-12-20 | US |
| (72) |
BJERREGAARD, Simon, DK
SAUERBERG, Per, DK
Seier, NIELSEN, Flemming, DK
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID |
| SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID |